The AGC Group is a global business conglomerate with over 206 companies, extending into over 30 countries with net sales of € 12,731 million (Y120 = €1) during 2021.
Under our long-term management strategy, Vision 2030, we aim to create sustainable economic and social value, enhance each business’s competitiveness, and build a solid and long-term stable earnings base. Business Process Excellence is embedded into our organization’s culture.
The group has over 40 years of CDMO experience. Through acquisitions and investments, Life Science has become a strategic pillar, with state-of-the-art innovative Research and Development (R&D) centers in Japan, Europe and the US, and multi-purpose facilities with a broad portfolio of technologies.
AGC acquired the former API plant of Boehringer Ingelheim in Malgrat de Mar, Spain. The plant has been operational as AGC Pharma Chemicals Europe, S.L.U. since the 1st March 2019. It is the first FDA registered site in Europe for AGC to help broaden its pharmaceutical CDMO business. Specializing in Process Development, scaling up, and optimization, the new R&D lab has been operational since March 2021 and has tripled capacity.
Our services are based on specialized technologies and complement production facilities that support customer projects. We are committed to the highest levels and cGMP quality standards.
AGC Pharma Chemicals focuses on:
Established in 1959 on the waterfront industrial park in Ichihara City, Chiba Prefecture, the plant was merged with AGC Inc in January 2009.
We have two cGMP plants supporting clinical phase projects and high-volume commercial phase manufacturing for APIs and Intermediates. Our multi-purpose facility is compatible with diverse processes, with a core structure and gravity-based facility design that guarantees flexibility and high quality.
The AGC Yokohama Technical Center (former Keihin Plant) started operation in 1916 at Tsurumi, Yokohama and was renewed and expanded in 2020. With more than 250 talented scientist, it is the center of global innovation within AGC and includes an R&D area for small molecule CDMO including HAPI handling where a team of 35 chemists supports AGC Pharma Chemicals.
Some of the capabilities:
Established in 1998 on the waterfront side in Obama City, Fukui Prefecture, AGC Wakasa Chemical has one cGMP compliant site and also non-GMP sites for Agrochemicals, registered starting materials and raw materials.
Our sister company for large molecules.
This facility offers vast experience with cGMP manufacturing for a large number of projects and specializes in:
For more information, check www.agcbio.com
Our customer focus and commitment drives us to know our clients, understand their needs and deliver value.
We challenge ourselves to deliver better results, achieve our goals, evolve and adapt to obstacles to find solutions.
We ensure that our activities and processes are carried out per the highest standards of excellence because we pride ourselves on demonstrating compliance with all applicable regulatory standards while investing in a continuous improvement culture.
We cooperate to achieve common goals, creating a positive, innovative and continuous learning environment that enables our teams to push for excellence.
We quickly adapt our business approaches to new situations because we are smart when it comes to flexibility.
We seek new perspectives and vision to implement creative solutions in new and different ways to achieve our goals.
Ana-Pilar González Salillas, PhD
Francesc Benjumea Parrilla
Production Operations and Logistic
Tom De Geyter, PhD
Sales and Business Development
Manel Doménech Arasanz
Juan Carlos Flecha Barrioluengo
Montse Magarzo Escursell
Quality & Regulatory Affairs
Carmen de Rosendo González
Enviroment, Health and Safety
Joan Vélez Carreño